Hers vs Henry Meds: GLP-1 Telehealth Provider Comparison
Compare Hers (FDA-approved brand-name) and Henry Meds (compounded). Pricing from $99/mo vs $199/mo. Insurance acceptance, shipping, FDA compliance.
Informational comparison only — not medical advice. Your prescriber decides what's right for you.
FDA Compliance Notice
Hers offers compounded GLP-1 medications. As of March 2026, the FDA has issued warning letters to multiple telehealth providers regarding compounded GLP-1 marketing. Discuss FDA-approved alternatives with your provider.
Learn more →We don't currently recommend Henry Meds.
They stay in this comparison because readers search for them, but we don't link to them as partners. See the providers we do recommend →
From
$99/mo
Score
8.0/10
From
$199/mo
Score
6.0/10
Quick answer
Compare Hers (FDA-approved brand-name) and Henry Meds (compounded). Pricing from $99/mo vs $199/mo. Insurance acceptance, shipping, FDA compliance.
- Hers FDA-approved for: See FDA label
- Henry Meds FDA-approved for: See FDA label
- Hers starting price: $99/month
- Henry Meds starting price: $199/month
Quick visual breakdown
Hers wins 2 · Henry Meds wins 0
Hers
2 of 4 wins
Henry Meds
0 of 4 wins
Side-by-side comparison
Neutral comparator. We run no clinic and never sell medication — we earn the same commission whoever you pick, so this ranking is editorial, not pay-to-rank. Methodology · How we make money
Where to start
Ranked by our editorial score. We earn a commission if you start a consultation through these links — it never changes your price.
$145/mo
Get from $145/mo$99/mo
Get from $99/mo$99/mo
Get from $99/mo$89/mo
Get from $89/mo
People also compare
Further reading (authoritative sources)
- Prescription medications to treat overweight & obesity — NIH — NIDDKGovernment overview of approved weight-management drugs.
- GLP-1 agonists — overview & how they work — NIH — MedlinePlus
- FDA's concerns with unapproved GLP-1 drugs used for weight loss — U.S. FDA
- Medicaid coverage of and spending on GLP-1s — KFFState-by-state coverage data (2026).